In 2010, Sigma Pharmaceutical restructured and sold its generic drug manufacturing business to South Africa’s Aspen Pharmacare for AUD$804 million, ending an almost 100-year legacy in the manufacturing field for the company.
In 2010, Sigma Pharmaceutical reorganized and sold its generic drug production business to Aspen Pharmacare of South Africa for AUD$804 million, marking the end of their century-long presence in the manufacturing industry.